PT-141: The Only FDA-Approved Peptide for Women's Sexual Desire
Hypoactive sexual desire disorder affects 1 in 10 women — rising to 1 in 4 after menopause. PT-141 (Vyleesi) is the first and only on-demand treatment that works on the brain's desire circuitry, not blood flow.
Low sexual desire isn't a personal failing. It's a neurological condition with biological roots — and for decades, medicine had essentially nothing to offer women who experienced it. Viagra worked for men by increasing blood flow. But female sexual desire doesn't originate in blood flow. It originates in the brain.
PT-141, marketed as Vyleesi (bremelanotide), changed that. Approved by the FDA in June 2019, it's the first and only on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike every other sexual health treatment on the market, it works centrally — activating melanocortin receptors in the hypothalamus that initiate the neurological cascade of sexual desire.
This is FemPeptides' flagship peptide for a reason: it's the only peptide with an FDA-approved indication specifically for women.
How PT-141 Works: Brain, Not Blood Flow
PT-141 is a melanocortin receptor agonist — it activates MC3R and MC4R receptors in the hypothalamus and limbic system, the brain regions that govern sexual motivation and reward. This activation triggers dopamine release in the nucleus accumbens, effectively priming the brain's reward system to respond to sexual stimuli.
This mechanism is fundamentally different from PDE5 inhibitors like Viagra or Cialis, which work peripherally by enhancing genital blood flow. It's also different from flibanserin (Addyi), the only other FDA-approved HSDD treatment, which works through serotonin/dopamine rebalancing and must be taken daily.
PT-141 is on-demand. You take it when you want it — approximately 45 minutes before anticipated sexual activity — rather than every day. This distinction matters for autonomy, side effect management, and the simple reality of how desire works in real life.
The Clinical Evidence
PT-141's approval was based on two Phase 3 clinical trials enrolling over 1,200 premenopausal women with HSDD. The results showed statistically significant increases in sexual desire scores, higher percentages of satisfying sexual encounters, and meaningful reductions in distress related to low desire compared to placebo.
The 1.75 mg subcutaneous dose was selected as the optimal benefit-risk ratio — producing significant efficacy with a manageable side effect profile. The most common side effects were nausea (40%, usually mild and transient), flushing (20%), and headache (11%). Most women reported that nausea diminished with subsequent uses.
PT-141 vs Other HSDD Treatments
| Feature | PT-141 (Vyleesi) | Flibanserin (Addyi) |
|---|---|---|
| Mechanism | Melanocortin receptor agonist (brain) | Serotonin/dopamine rebalancing |
| Dosing | On-demand (as needed) | Daily pill |
| Onset | ~45 minutes | 4–8 weeks for full effect |
| Alcohol | No restrictions | Cannot drink alcohol |
| Route | Subcutaneous injection | Oral tablet |
| FDA Status | Approved 2019 for HSDD | Approved 2015 for HSDD |
Who Is PT-141 For?
PT-141 is FDA-approved for premenopausal women with HSDD — defined as persistently low sexual desire that causes personal distress and is not attributed to other medical conditions, medications, or relationship factors. It's not an aphrodisiac and it doesn't create desire from nothing — it restores the brain's capacity to experience desire in response to appropriate stimuli.
For perimenopausal and menopausal women, PT-141 is used off-label. The neurological mechanism doesn't depend on premenopausal hormone levels, and many providers prescribe it across the menopausal transition with favorable results. However, formal clinical trial data in postmenopausal women is limited.
The Bigger Picture: Why This Matters
HSDD has been historically undertreated because medicine lacked tools to address it and because female sexual desire was poorly understood by a field that devoted decades to solving male erectile dysfunction. PT-141's approval represented a paradigm shift — acknowledging that desire is neurological, that HSDD is a real condition, and that women deserve evidence-based treatment options.
For women whose low desire traces back to brain-based mechanisms rather than relationship dynamics or hormonal deficiency, PT-141 fills a gap that nothing else does.
Where to Source PT-141
PT-141 is available through BioPure with code POWER. It requires a prescription for FDA-approved Vyleesi; research-grade is available from peptide suppliers.